Published in Oncoimmunology on March 01, 2012
Therapeutic opportunities for manipulating T(Reg) cells in autoimmunity and cancer. Nat Rev Drug Discov (2013) 1.50
Targeting tumor-stromal interactions in bone metastasis. Pharmacol Ther (2013) 1.12
CXCL12/CXCR4: a symbiotic bridge linking cancer cells and their stromal neighbors in oncogenic communication networks. Oncogene (2015) 1.07
Basic principles of tumor-associated regulatory T cell biology. Trends Immunol (2012) 1.05
Integrating new discoveries into the "vicious cycle" paradigm of prostate to bone metastases. Cancer Metastasis Rev (2014) 1.00
Natural killer cells generated from cord blood hematopoietic progenitor cells efficiently target bone marrow-residing human leukemia cells in NOD/SCID/IL2Rg(null) mice. PLoS One (2013) 0.94
Convergences and divergences of thymus- and peripherally derived regulatory T cells in cancer. Front Immunol (2013) 0.91
Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells. Oncoimmunology (2015) 0.88
Molecular regulation of bone marrow metastasis in prostate and breast cancer. Bone Marrow Res (2014) 0.84
Exosomes from bulk and stem cells from human prostate cancer have a differential microRNA content that contributes cooperatively over local and pre-metastatic niche. Oncotarget (2016) 0.84
Bone marrow as a metastatic niche for disseminated tumor cells from solid tumors. Bonekey Rep (2015) 0.81
New immune therapy targets tumor-associated environment: from bone marrow to tumor site. Cell Mol Immunol (2011) 0.80
Role of RANKL/RANK in primary and secondary breast cancer. World J Orthop (2013) 0.79
CXCR4 expression on pathogenic T cells facilitates their bone marrow infiltration in a mouse model of aplastic anemia. Blood (2015) 0.78
Tumor immunology: multidisciplinary science driving basic and clinical advances. Cancer Immunol Res (2013) 0.78
Bone specific immunity and its impact on metastasis. Bonekey Rep (2015) 0.78
Consumption of Soy Isoflavone Enriched Bread in Men with Prostate Cancer Is Associated with Reduced Proinflammatory Cytokines and Immunosuppressive Cells. Cancer Prev Res (Phila) (2015) 0.77
KLRG1 restricts memory T cell antitumor immunity. Oncotarget (2016) 0.75
RANK/RANKL pathway in cancer: Biological activity beyond bone? J Bone Oncol (2012) 0.75
CD4(+)CD25(hi)CD127(-) Treg and CD4(+)CD45R0(+)CD49b(+)LAG3(+) Tr1 cells in bone marrow and peripheral blood samples from children with neuroblastoma. Oncoimmunology (2016) 0.75
Tumor specific regulatory T cells in the bone marrow of breast cancer patients selectively upregulate the emigration receptor S1P1. Cancer Immunol Immunother (2017) 0.75
Programmed differentiated natural killer cells kill leukemia cells by engaging SLAM family receptors. Oncotarget (2017) 0.75
Overcoming Oncogenic Mediated Tumor Immunity in Prostate Cancer. Int J Mol Sci (2017) 0.75
Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat Rev Immunol (2017) 0.75
Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med (2003) 26.05
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med (2004) 22.96
Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med (2009) 13.57
Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer (2005) 10.06
Denosumab in postmenopausal women with low bone mineral density. N Engl J Med (2006) 10.02
Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol (2006) 9.42
Suppressor effector function of CD4+CD25+ immunoregulatory T cells is antigen nonspecific. J Immunol (2000) 9.15
Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature (1999) 8.23
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med (2003) 7.35
CD4+CD25+ T cells inhibit both the induction and effector function of autoreactive T cells and represent a unique lineage of immunoregulatory cells. J Immunol (1998) 7.31
Humoral immunity due to long-lived plasma cells. Immunity (1998) 6.35
G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nat Immunol (2002) 6.22
Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol (2006) 6.13
Identifying Foxp3-expressing suppressor T cells with a bicistronic reporter. Proc Natl Acad Sci U S A (2005) 5.96
Selective depletion of Foxp3+ regulatory T cells induces a scurfy-like disease. J Exp Med (2007) 5.52
Tolerance, not immunity, crucially depends on IL-2. Nat Rev Immunol (2004) 5.24
Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res (2002) 5.00
Interleukin 2 signaling is required for CD4(+) regulatory T cell function. J Exp Med (2002) 3.94
Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nat Med (2001) 3.81
B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J Exp Med (2006) 3.75
NF-kappaB in breast cancer cells promotes osteolytic bone metastasis by inducing osteoclastogenesis via GM-CSF. Nat Med (2006) 3.40
Bone marrow is a major reservoir and site of recruitment for central memory CD8+ T cells. Immunity (2005) 3.39
Osteoimmunology: interplay between the immune system and bone metabolism. Annu Rev Immunol (2006) 3.18
Epidermal RANKL controls regulatory T-cell numbers via activation of dendritic cells. Nat Med (2006) 3.09
Regulatory T cells protect from local and systemic bone destruction in arthritis. J Immunol (2010) 2.70
Cutting edge: induction of B7-H4 on APCs through IL-10: novel suppressive mode for regulatory T cells. J Immunol (2006) 2.50
Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest (2001) 2.49
Skeletal localization and neutralization of the SDF-1(CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo. J Bone Miner Res (2004) 2.36
Bone marrow is a reservoir for CD4+CD25+ regulatory T cells that traffic through CXCL12/CXCR4 signals. Cancer Res (2004) 2.28
Cutting edge: opposite effects of IL-1 and IL-2 on the regulation of IL-17+ T cell pool IL-1 subverts IL-2-mediated suppression. J Immunol (2007) 2.21
Pancreatic lymph node-derived CD4(+)CD25(+) Treg cells: highly potent regulators of diabetes that require TRANCE-RANK signals. Immunity (2002) 2.20
Increasing tumor antigen expression overcomes "ignorance" to solid tumors via crosspresentation by bone marrow-derived stromal cells. Immunity (2002) 2.18
Treg cells suppress osteoclast formation: a new link between the immune system and bone. Arthritis Rheum (2007) 2.12
Bone marrow as a priming site for T-cell responses to blood-borne antigen. Nat Med (2003) 2.01
Bone marrow is a preferred site for homeostatic proliferation of memory CD8 T cells. J Immunol (2005) 1.95
Therapy of human tumors in NOD/SCID mice with patient-derived reactivated memory T cells from bone marrow. Nat Med (2001) 1.88
Bone turnover mediates preferential localization of prostate cancer in the skeleton. Endocrinology (2005) 1.85
Interleukin-2 administration alters the CD4+FOXP3+ T-cell pool and tumor trafficking in patients with ovarian carcinoma. Cancer Res (2007) 1.66
Selective depletion of Foxp3+ regulatory T cells improves effective therapeutic vaccination against established melanoma. Cancer Res (2010) 1.66
FOXP3 defines regulatory T cells in human tumor and autoimmune disease. Cancer Res (2009) 1.63
Stromal factors involved in prostate carcinoma metastasis to bone. Cancer (2003) 1.63
Vigorous premalignancy-specific effector T cell response in the bone marrow of patients with monoclonal gammopathy. J Exp Med (2003) 1.44
Bone marrow can function as a lymphoid organ during a primary immune response under conditions of disrupted lymphocyte trafficking. J Immunol (1997) 1.27
Immunodominance and tumor escape. Semin Cancer Biol (2002) 1.24
Development of anti-p185HER2 immunoliposomes for cancer therapy. Proc Natl Acad Sci U S A (1995) 1.18
Bone marrow and the control of immunity. Cell Mol Immunol (2011) 1.15
Enrichment of memory T cells and other profound immunological changes in the bone marrow from untreated breast cancer patients. Int J Cancer (2001) 1.03
Osteoblasts induce prostate cancer proliferation and PSA expression through interleukin-6-mediated activation of the androgen receptor. Clin Exp Metastasis (2004) 0.98
Reversal of chemotherapy-induced leukopenia using granulocyte macrophage colony-stimulating factor promotes bone metastasis that can be blocked with osteoclast inhibitors. Cancer Res (2010) 0.89
Intraosseous injection of RM1 murine prostate cancer cells promotes rapid osteolysis and periosteal bone deposition. Clin Exp Metastasis (2008) 0.88
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med (2004) 22.96
The mutational landscape of head and neck squamous cell carcinoma. Science (2011) 16.88
In vivo depletion of CD11c+ dendritic cells abrogates priming of CD8+ T cells by exogenous cell-associated antigens. Immunity (2002) 14.57
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med (2003) 7.35
Efficient mapping of mendelian traits in dogs through genome-wide association. Nat Genet (2007) 5.99
Selective depletion of Foxp3+ regulatory T cells induces a scurfy-like disease. J Exp Med (2007) 5.52
Card9 controls a non-TLR signalling pathway for innate anti-fungal immunity. Nature (2006) 5.34
Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med (2013) 5.29
Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res (2002) 5.00
Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med (2011) 4.93
Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood (2009) 4.80
The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell (2009) 4.47
Endogenous IL-17 contributes to reduced tumor growth and metastasis. Blood (2009) 4.13
The developmental dynamics of the maize leaf transcriptome. Nat Genet (2010) 4.02
Intestinal tolerance requires gut homing and expansion of FoxP3+ regulatory T cells in the lamina propria. Immunity (2011) 3.92
Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment. J Immunol (2007) 3.81
B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J Exp Med (2006) 3.75
IL-7 engages multiple mechanisms to overcome chronic viral infection and limit organ pathology. Cell (2011) 3.61
NF-kappaB in breast cancer cells promotes osteolytic bone metastasis by inducing osteoclastogenesis via GM-CSF. Nat Med (2006) 3.40
A requirement for CARMA1 in TCR-induced NF-kappa B activation. Nat Immunol (2002) 3.38
Phosphorylation-dependent ubiquitylation and degradation of androgen receptor by Akt require Mdm2 E3 ligase. EMBO J (2002) 3.27
Induction of IL-17+ T cell trafficking and development by IFN-gamma: mechanism and pathological relevance in psoriasis. J Immunol (2008) 3.22
Reference genome sequence of the model plant Setaria. Nat Biotechnol (2012) 3.21
Effects of raf kinase inhibitor protein expression on suppression of prostate cancer metastasis. J Natl Cancer Inst (2003) 3.19
Priming in systemic plant immunity. Science (2009) 3.11
Generation and characterization of androgen receptor knockout (ARKO) mice: an in vivo model for the study of androgen functions in selective tissues. Proc Natl Acad Sci U S A (2002) 3.08
Suppression of autophagy by FIP200 deletion inhibits mammary tumorigenesis. Genes Dev (2011) 3.05
Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin Cancer Res (2004) 2.96
Reciprocal differentiation and tissue-specific pathogenesis of Th1, Th2, and Th17 cells in graft-versus-host disease. Blood (2009) 2.91
PYPAF1, a PYRIN-containing Apaf1-like protein that assembles with ASC and regulates activation of NF-kappa B. J Biol Chem (2002) 2.88
The relationship of eosinophilia to intravenous immunoglobulin treatment failure in Kawasaki disease. Pediatr Allergy Immunol (2007) 2.81
T cell receptor stimulation-induced epigenetic changes and Foxp3 expression are independent and complementary events required for Treg cell development. Immunity (2012) 2.78
In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses. Nat Biotechnol (2009) 2.76
An IL-9 fate reporter demonstrates the induction of an innate IL-9 response in lung inflammation. Nat Immunol (2011) 2.69
Functional screening of five PYPAF family members identifies PYPAF5 as a novel regulator of NF-kappaB and caspase-1. FEBS Lett (2002) 2.66
Triple versus dual antiplatelet therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Circulation (2009) 2.62
Cutting edge: induction of B7-H4 on APCs through IL-10: novel suppressive mode for regulatory T cells. J Immunol (2006) 2.50
Androgen receptor is a tumor suppressor and proliferator in prostate cancer. Proc Natl Acad Sci U S A (2008) 2.47
Inferring reputation promotes the evolution of cooperation in spatial social dilemma games. PLoS One (2012) 2.41
CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers. Cancer Res (2005) 2.38
Stroma-derived factor (SDF-1/CXCL12) and human tumor pathogenesis. Am J Physiol Cell Physiol (2006) 2.36
Skeletal localization and neutralization of the SDF-1(CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo. J Bone Miner Res (2004) 2.36
Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol (2005) 2.34
Influence of the period-dependent circadian clock on diurnal, circadian, and aperiodic gene expression in Drosophila melanogaster. Proc Natl Acad Sci U S A (2002) 2.33
Prostate cancer cells promote osteoblastic bone metastases through Wnts. Cancer Res (2005) 2.32
First-in-human trial of a STAT3 decoy oligonucleotide in head and neck tumors: implications for cancer therapy. Cancer Discov (2012) 2.31
Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers. Cancer Discov (2013) 2.29
Bone marrow is a reservoir for CD4+CD25+ regulatory T cells that traffic through CXCL12/CXCR4 signals. Cancer Res (2004) 2.28
Helicobacter pylori immune escape is mediated by dendritic cell-induced Treg skewing and Th17 suppression in mice. Gastroenterology (2009) 2.22
Tunneling and coupled motion in the Escherichia coli dihydrofolate reductase catalysis. J Am Chem Soc (2004) 2.21
Cutting edge: opposite effects of IL-1 and IL-2 on the regulation of IL-17+ T cell pool IL-1 subverts IL-2-mediated suppression. J Immunol (2007) 2.21
Association between the various mutations in viral core promoter region to different stages of hepatitis B, ranging of asymptomatic carrier state to hepatocellular carcinoma. Am J Gastroenterol (2010) 2.20
Cutting edge: depletion of Foxp3+ cells leads to induction of autoimmunity by specific ablation of regulatory T cells in genetically targeted mice. J Immunol (2009) 2.17
Tolerance rather than immunity protects from Helicobacter pylori-induced gastric preneoplasia. Gastroenterology (2010) 2.17
Re-emerging superconductivity at 48 kelvin in iron chalcogenides. Nature (2012) 2.13
Low-molecular-weight heparin versus unfractionated heparin in acute ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention with drug-eluting stents. Am Heart J (2010) 2.09
Plasmacytoid dendritic cells induce CD8+ regulatory T cells in human ovarian carcinoma. Cancer Res (2005) 2.06
Stromal cells in tumor microenvironment and breast cancer. Cancer Metastasis Rev (2013) 2.05
Expression of aldehyde dehydrogenase and CD133 defines ovarian cancer stem cells. Int J Cancer (2011) 2.05
CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis. Cancer Res (2011) 2.03
Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma. Cancer Res (2007) 2.01
Effects of estrogen depletion on angiogenesis in estrogen-receptor-positive breast carcinoma--an immunohistochemical study of vasohibin-1 and CD31 with correlation to pathobiological response of the patients in neoadjuvant aromatase inhibitor therapy. Expert Opin Ther Targets (2012) 2.00
Human TH17 cells are long-lived effector memory cells. Sci Transl Med (2011) 1.99
Nucleation and growth of nanoparticles in the atmosphere. Chem Rev (2011) 1.99
DC activated via dectin-1 convert Treg into IL-17 producers. Eur J Immunol (2008) 1.99
Regulatory T cells in ovarian cancer: biology and therapeutic potential. Am J Reprod Immunol (2005) 1.96
MT1-MMP-dependent control of skeletal stem cell commitment via a β1-integrin/YAP/TAZ signaling axis. Dev Cell (2013) 1.95
Increased prostate cell proliferation and loss of cell differentiation in mice lacking prostate epithelial androgen receptor. Proc Natl Acad Sci U S A (2007) 1.93
Suppression versus induction of androgen receptor functions by the phosphatidylinositol 3-kinase/Akt pathway in prostate cancer LNCaP cells with different passage numbers. J Biol Chem (2003) 1.90
Targeting Stat3 abrogates EGFR inhibitor resistance in cancer. Clin Cancer Res (2012) 1.89
Maturation of lymph node fibroblastic reticular cells from myofibroblastic precursors is critical for antiviral immunity. Immunity (2013) 1.89
Regulatory T cells increase the avidity of primary CD8+ T cell responses and promote memory. Science (2012) 1.88
Hepatic resection as a safe and effective treatment for hepatocellular carcinoma involving a single large tumor, multiple tumors, or macrovascular invasion. Medicine (Baltimore) (2015) 1.88
Regulatory T-cell compartmentalization and trafficking. Blood (2006) 1.86
Bone turnover mediates preferential localization of prostate cancer in the skeleton. Endocrinology (2005) 1.85
Role of differentiation of liver sinusoidal endothelial cells in progression and regression of hepatic fibrosis in rats. Gastroenterology (2011) 1.85